Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications.

Abstract	Long-term trials with BAY 12-9566, a stromelysin inhibitor, have been initiated in osteoarthritis. Validation of the long-term, clinical relevance of early markers has to be tested in these and other trials. Detection of the slowing of cartilage loss (as gauged by measures of joint space narrowing and by other techniques, such as MRI) remains to be proven, but now may be possible in intervention trials.
Authors	R L Leff
Journal	Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 878 Pg. 201-7 (Jun 30 1999) ISSN: 0077-8923 [Print] United States
PMID	10415731 (Publication Type: Journal Article, Review)
Chemical References	Antineoplastic Agents Biomarkers Biphenyl Compounds Matrix Metalloproteinase Inhibitors Organic Chemicals Phenylbutyrates Protease Inhibitors Bay 12-9566
Topics	Animals Antineoplastic Agents (adverse effects, therapeutic use) Biomarkers Biphenyl Compounds Cartilage (metabolism) Clinical Trials as Topic Extracellular Matrix (enzymology) Humans Matrix Metalloproteinase Inhibitors Organic Chemicals Osteoarthritis (drug therapy) Phenylbutyrates Protease Inhibitors (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!